TILT Biotherapeutics Ltd

TILT Biotherapeutics Ltd is a clinical-stage biotechnology company based in Helsinki, Finland, with a presence in Cambridge, Massachusetts.

Founded in 2013, the company focuses on developing innovative cancer immunotherapies, particularly through its proprietary TILT® technology platform. This platform utilizes oncolytic adenoviruses to activate T cells and target cancer cells, transforming "cold" tumors into "hot" tumors that are more susceptible to immune attack. The company has raised over EUR 72 million from various investors, including the European Innovation Council Fund and the U.S. Department of Defense. TILT Biotherapeutics is advancing its products through clinical trials, with a strong emphasis on enhancing the efficacy of existing therapies like immune checkpoint inhibitors and CAR T-cell therapy. Its target markets include hospitals, cancer treatment centers, and research institutions in Europe and the USA, aiming to provide effective treatments for patients with solid tumors, including those resistant to conventional therapies.